Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemtabrutinib - Merck

Next Previous
Drug Profile

Nemtabrutinib - Merck

Alternative Names: ARQ-531; MK-1026

Latest Information Update: 30 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArQule
  • Developer Merck & Co
  • Class Antineoplastics; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Follicular lymphoma; Haematological malignancies; Richter's syndrome

Most Recent Events

  • 26 Sep 2025 Fred Hutchinson Cancer Center plans a phase II trial for Chronic lymphocytic leukemia (Adjunctive treatment, Recurrent, Second-line therapy or greater) in USA (PO) (NCT07194980)
  • 03 Sep 2025 Merck Sharp & Dohme completes a phase I trials in Haematological malignancies (Second-line therapy or greater) in Japan (PO) (NCT05673460; jRCT2031220583)
  • 03 Mar 2025 Pharmacodynamics data from preclinical studies in Cancer presented at the ESMO Targeted Anticancer Therapies Congress 2025 (ESMO TAT-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top